The company attributed the revenue surge to its launch in the Canadian consumer market, where it reported sales of C$21.6 million, and international medical markets. Aurora said it accounted for 20% of consumer sales in Canada. Aurora projected it will reach sustained positive EBITDA beginning in its fiscal fourth quarter.